Therapeutic schemes to combat Covid-19: systematic review

Authors

DOI:

https://doi.org/10.33448/rsd-v10i1.11533

Keywords:

COVID-19; SARS-CoV-2; Clinical management; Antiviral drugs.

Abstract

The aim of this study was to investigate the main therapeutic regimens used so far in the Covid-19 fight on the world stage. Is a systematic literature review conducted in ScienceDirect, Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs) and Scientific Electronic Library Online (SciELO) databases, using the term “treatment Covid-19”, carried out in April 2020. We selected 16 articles according to the inclusion criteria: research articles, published between February 2019 and April 2020, without distinction of languages. The work was organized according to PRISMA recommendations, registered in PROSPERO. The articles found, ranged from in vitro, in silico, open clinical trials, cohort, retrospective and analytical, and were conducted in China, France, India, Saudi Arabia and South Korea, with the highest number of Chinese publications (70.5%). Samples range from one to 199 people, all infected with the SARS-CoV-2 virus, with a higher percentage of females (51.7%), ages 18 to 88 years. Medicines like lopinavir, ritonavir, favipiravir, arbidol, costicoteroids, hydroxychloroquine, recipes of traditional Chinese medicine, glycirrizine, azithromycin, and tocilizumab were analyzed in studies in a monotherapeutic or associated form, as well as mesenchyhimsal stem cell transplantation, intensive plasma exchange and intravenous immunoglobulin. There were divergences and complementation of results among the authors. Despite presenting findings and assisting in the fight against the pandemic, current studies present promising drugs for the treatment of symptomatology and viral load, with the objective of identifying an ideal treatment for the disease, not obtaining consensus.

References

Arabi, Y. M., Mandourah, Y., Al-Hameed, F., Sindi, A. A., Almekhlafi, G. A., Hussein, M. A., Jose, J., Pinto, R., Al-Omari, A., Kharaba, A., Almotairi, A., Al Khatib, K., Alraddadi, B., Shalhoub, S., Abdulmomen, A., Qushmaq, I., Mady, A., Solaiman, O., Al-Aithan, A. M., Fowler, R. A., the Saudi Critical Care Trial Group (2018). Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. American Journal of Respiratory and Critical Care Medicine, 197(6), 757–767.

Boriskin, Y., Leneva, I., Pecheur, E. I., & Polyak, S. (2008). Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Current Medicinal Chemistry, 15(10), 997–1005.

Brasil. Ministério da Saúde. (2020). Diretrizes para diagnóstico e tratamento da COVID-19 (Vol. 4). Brasília, DF: Ministério da Saúde. https://portalarquivos.saude.gov.br/images/pdf/2020/May/08/Diretriz-Covid19-v4-07-05.20h05m.pdf

Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Q., Yang, Y., Shen, C., Li, X., Peng, L., Huang, D., Zhang, J., Zhang, S., Wang, F., Liu, J., Chen, L., Chen, S., & Liu, L. (2020). Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering, 6(10); 4–10.

Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li, X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., Yuan, Y., & Wang, D. Z. C. (2020). A lopinavir-ritonavir trial in adults hospitalized with severe Covid-19. The New England Journal of Medicine, 382(19), 1787-1799.

Cespedes, M. da S., & Souza, J. C. (2020). SARS-CoV-2: uma revisão para o clínico. SciELO Preprints, 1(1), 1–17.

Chan, K. W., Wong, V. T., & Tang, S. C. W. (2020). COVID-19: An update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese–Western medicine for the management of 2019 novel coronavirus disease. The American Journal of Chinese Medicine, 48(3), 737–762.

Chen, J., Hu, C., Chen, L., Tang, L., Zhu, Y., Xu, X., Chen, L., Gao, H., Lu, X., Yu, L., Dai, X., Xiang, C., & Li, L. (2020). Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: a hint for COVID-19 treatment. Engineering, 6(10), 1153–1161.

Deng, L., Li, C., Zeng, Q., Liu, X., Li, X., Zhang, H., Hong, Z., & Xia, J. (2020). Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. Journal of Infection, 81(1), e1–e5.

Elfiky, A. A. (2020). Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sciences, 248, 117477.

Epidemiology Working Group for NCIP Epidemic Response, C. C. for D. C. and P. (2020). [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi, 41(2), 145–151.

Fehr, A. R., & Perlman, S. (2015). Coronaviruses: an overview of their replication and pathogenesis. In H. J. Maier, E. Bickerton, & P. Britton (Eds.), Coronaviruses: methods and protocols (Vol. 1282, Issue 1). Springer.

Galvão, T. F., Pansani, T. de S. A., & Harrad, D. (2015). Principais itens para relatar Revisões sistemáticas e meta-análises: a recomendação PRISMA. Epidemiologia e Serviços de Saúde, 24(2), 335–342.

Gautret, P., Lagier, J. C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Tissot Dupont, H., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, J. M., Brouqui, P., & Raoult, D. (2020a). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 56(1), 105949.

Gautret, P., Lagier, J., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Tissot Dupont, H., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, J., Brouqui, P., & Raoult, D. (2020b). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 56(1), 105949.

Gorbalenya, A., Baker, S., Baric, R., de Groot, R., Drosten, C., Gulyaeva, A., Haagmans, B., Lauber, C., Leontovich, A., Neuman, B., Penzar, D., Perlman, S., Poon, L., Samborskiy, D., Sidorov, I., Sola, I., & Ziebuhr, J. (2020). Severe acute respiratory syndrome-related coronavirus : The species and its viruses – a statement of the Coronavirus Study Group. Nature Microbiology. https://www.biorxiv.org/content/10.1101/2020.02.07.937862v1

Guo, Y. R., Cao, Q. D., Hong, Z. S., Tan, Y. Y., Chen, S. D., Jin, H. J., Tan, K. S., Wang, D. Y., & Yan, Y. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medical Research, 7(1), 11.

Karami, P., Naghavi, M., Feyzi, A., Aghamohammadi, M., Novin, M. S., Mobaien, A., Qorbanisani, M., Karami, A., & Norooznezhad, A. H. (2020). Mortality of a pregnant patient diagnosed with COVID-19: A case report with clinical, radiological, and histopathological findings. Travel Medicine and Infectious Disease, 101665.

Khamitov, R. A., Loginova, S. I., Shchukina, V. N., Borisevich, S. V, Maksimov, V. A., & Shuster, A. M. (2020). Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Voprosy Virusologii, 53(4), 9–13.

Li, X., Geng, M., Peng, Y., Meng, L., & Lu, S. (2020). Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis, 10(2), 102–108.

Lim, J., Jeon, S., Shin, H. Y., Kim, M. J., Seong, Y. M., Lee, W. J., Choe, K. W., Kang, Y. M., Lee, B., & Park, S. J. (2020a). The author’s response: case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. Journal of Korean Medical Science, 35(7), 1–6.

Lim, J., Jeon, S., Shin, H., Kim, M. J., Seong, Y. M., Lee, W. J., Choe, K., Kang, Y. M., Lee, B., & Park, S. (2020b). Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. Journal of Korean Medical Science, 35(6), 1–6.

Luo, P., Liu, D., & Li, J. (2020). Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19. International Journal of Antimicrobial Agents, 55(6), 105995.

Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D., & Li, J. (2020). Tocilizumab treatment in COVID‐19: A single center experience. Journal of medical virology, 92(7), 814-818.

Lu, S., Lin, J., Zhang, Z., Xiao, L., Jiang, Z., Chen, J., Hu, C., & Luo, S. (2020). Alert for non-respiratory symptoms of Coronavirus Disease 2019 (COVID-19) patients in epidemic period: A case report of familial cluster with three asymptomatic COVID-19 patients. Journal of Medical Virology, 2019, 1-4.

Mcintosh, K., & Bloom, A. (2020). Doença de coronavírus 2019 (COVID-19). UpToDate, 2019. http://www.toledo.ufpr.br/portal/wp-content/uploads/2020/04/Doença-por-coronv%C3%ADrus-2019-UPTODATE.pdf

Oestereich, L., Lüdtke, A., Wurr, S., Rieger, T., Muñoz-Fontela, C., & Günther, S. (2014). Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Research, 105(1), 17–21.

Perlman, S., & Netland, J. (2009). Coronaviruses post-SARS: update on replication and pathogenesis. Nature Reviews Microbiology, 7(6), 439–450. https://doi.org/10.1038/nrmicro2147

Pfefferle, S., Reucher, S., Nörz, D., & Lütgehetmann, M. (2020). Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system. Eurosurveillance, 25(9), 1–5.

Ramos, L. M. da C. de S., Faustino, M. V. de A. S., Silva, J. M. A. da, & Freitas, G. R. M. de. (2020). O surto do novo coronavírus (2019-nCoV) e a COVID19. Paraíba: Centro de Informação de Medicamentos da Universidade Federal da Paraíba. https://www.ufpb.br/cim/contents/menu/publicacoes/cimforma/o-surto-do-novo-coronavirus-2019-ncov-e-a-covid19

Ren, J., Zhang, A. H., & Wang, X. J. (2020). Traditional Chinese medicine for COVID-19 treatment. Pharmacological Research, 155(January), 104743.

Runfeng, L., Yunlong, H., Jicheng, H., Weiqi, P., Qinhai, M., Yongxia, S., Chufang, L., Jin, Z., Zhenhua, J., Haiming, J., Kui, Z., Shuxiang, H., Jun, D., Xiaobo, L., Xiaotao, H., Lin, W., Nanshan, Z., & Zifeng, Y. (2020). Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacological Research, 156, 104761.

Sarzi-Puttini, P., Giorgi, V., Sirotti, S., Marotto, D., Ardizzone, S., Rizzardini, G., Antinori, S., & Galli, M. (2020). COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clinical and Experimental Rheumatology, 38(2), 337–342.

Shah, B., Modi, P., & Sagar, S. R. (2020). In silico studies on therapeutic agents for COVID-19: Drug repurposing approach. Life Sciences, 252, 117652.

Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ, 349(jan02 1), g7647–g7647.

Shi, H., Zhou, C., He, P., Huang, S., Duan, Y., Wang, X., Lin, K., Zhou, C., Zhang, X., & Zha, Y. (2020). Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-19. International Journal of Antimicrobial Agents, 56(2), 105974.

Singhal, T. (2020). Review on COVID19 disease so far. The Indian Journal of Pediatrics, 87(April), 281–286.

Teixeira, M. Z. (2020). Protocolo de pesquisa clínica para avaliar a eficácia e a segurança de medicamento homeopático individualizado no tratamento e na prevenção da epidemia de COVID-19 TT - Clinical research protocol to evaluate the efficacy and safety of individualized home. Portal Regional da BVS, 62. https://doi.org/10.13140/RG.2.2.26359.37281/3

Wang, Z., Chen, X., Lu, Y., Chen, F., & Zhang, W. (2020). Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. BioScience Trends, 14(1), 64–68.

Zheng, C., Wang, J., Guo, H., Lu, Z., Ma, Y., Zhu, Y., Xia, D., Wang, Y., He, H., Zhou, J., Wang, Y., Fei, M., Yin, Y., Zheng, M., & Xu, Y. (2020). Risk-adapted Treatment Strategy For COVID-19 Patients. International Journal of Infectious Diseases, 94, 74–77.

Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., Si, H. R., Zhu, Y., Li, B., Huang, C. L., Chen, H. D., Chen, J., Luo, Y., Guo, H., Jiang, R. D., Liu, M. Q., Chen, Y., Shen, X. R., Wang, X., Zheng, X. S., & Shi, Z. L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270–273.

Zhu, Z., Lu, Z., Xu, T., Chen, C., Yang, G., Zha, T., Lu, J., & Xue, Y. (2020). Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. Journal of Infection, 81(1), e21–e23.

Zu, Z. Y., Jiang, M. D., Xu, P. P., Chen, W., Ni, Q. Q., Lu, G. M., & Zhang, L. J. (2020). Coronavirus disease 2019 (COVID-19): A Perspective from China. Radiology, 296(2), E15–E25.

Downloads

Published

08/01/2021

How to Cite

ZUIL, D. M. .; FONTOURA, V. M. .; SANTOS, F. S. .; SANTOS NETO, M.; PASCOAL, L. M. .; MARTINS, M. C. N. S. E. .; FONTOURA, M. G. .; DIAS, A. R. D. .; LIMA, C. C. D. .; GRAEPP-FONTOURA, I. Therapeutic schemes to combat Covid-19: systematic review. Research, Society and Development, [S. l.], v. 10, n. 1, p. e21310111533, 2021. DOI: 10.33448/rsd-v10i1.11533. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/11533. Acesso em: 19 apr. 2024.

Issue

Vol. 10 No. 1

Section

Health Sciences

License

Copyright (c) 2021 Danielli Marinho Zuil; Volmar Morais Fontoura; Floriacy Stabnow Santos; Marcelino Santos Neto; Lívia Maia Pascoal; Márcia Caroline Nascimento Sá Ewerton Martins; Maikon Graepp Fontoura; Alzira Regina Dantas Dias; Cynthia Cardozo Dias Lima; Iolanda Graepp-Fontoura

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.